🔬 100K+ researchers trust BodyHackGuide — Join r/BodyHackGuide

HormonePreclinical

DHEA Dosage Guide: Protocols, Calculator & Safety

Everything you need to know about DHEA dosing — protocols, safety, and where to buy.

Dosage Calculator

Calculate exact dosing for DHEA.

Dosing Protocols

Beginner

The Beginner Protocol establishes DHEA as a targeted intervention rather than a routine supplement. DHEA is a hormone, not a vitamin or amino acid — it should have a clear rationale before initiation and ideally clinical confirmation of indication.

Who should consider DHEA — reasonable candidates:

Adults over 40 with documented low DHEA-S (lab value below age-appropriate reference range)
Post-menopausal women with specific symptoms: vaginal atrophy, sexual dysfunction, low libido, midlife depression
Men over 50 with low energy, reduced libido, and documented low DHEA-S
Adults with confirmed adrenal insufficiency (under endocrinology care)
Peri-menopausal women with mood concerns and low DHEA-S

Who should NOT start DHEA without specialist guidance:

Individuals under 30 (baseline DHEA-S typically already adequate)
Anyone with history of hormone-sensitive cancer (breast, prostate, endometrial, ovarian)
Men with prostate nodules, elevated PSA, or active prostate concerns
Pregnant, nursing, or pregnancy-planning women
Individuals with severe liver disease
Competitive athletes subject to drug testing
Children and adolescents

Week 0 — Baseline:

Obtain DHEA-S lab value (standard commercial lab test, typically $30-50 without insurance)
Reference ranges vary by age and sex but generally: young adults (20-30) 200-500 μg/dL; middle-aged 100-300 μg/dL; older adults 50-200 μg/dL
Also obtain: total and free testosterone (men), estradiol (both sexes over 50), lipid panel, CBC, CMP
Men: PSA; Women: confirm current mammography and pelvic exam status
Discuss with primary care physician or a physician familiar with hormonal therapy before starting

Starting dose — conservative:

Women: start at 5mg/day oral DHEA in the morning
Men: start at 25mg/day oral DHEA in the morning
Use micronized DHEA from a reputable brand (Pure Encapsulations, Thorne, Nature's Way, Life Extension, Double Wood) or pharmaceutical-grade where available
Avoid megadose products (100mg+ tablets) unless specifically prescribed
Take with food for GI comfort; morning dosing avoids sleep disruption

Week 1-2: Take consistent daily dose. Monitor for:

Subjective effects: energy levels, mood, libido, sleep
Side effects: acne, oily skin, facial hair (women), sleep disruption, mood changes
Any adverse symptoms warrant immediate dose reduction or discontinuation

Week 3-4:

If well-tolerated and benefits are clearly present, continue at starting dose
If benefits feel minimal and tolerance is good, consider modest dose increase:
- Women: to 10-15mg/day
- Men: to 50mg/day (usually the ceiling for general supplementation)
If significant side effects (acne, hirsutism, sleep issues), reduce dose or discontinue

Week 6-8 — Follow-up labs:

Repeat DHEA-S to confirm level has risen into target range
Target: DHEA-S in the upper half of age-appropriate reference range, not supraphysiological
If DHEA-S is well above age-appropriate range, reduce dose
Women on DHEA: consider checking estradiol and testosterone for supraphysiological elevation
Men on DHEA: consider checking estradiol (excessive aromatization) and testosterone
Any side effects warrant dose adjustment or discontinuation

Week 12 and beyond — Maintenance:

Once stable dose and response are established, continue with periodic monitoring
Annual: comprehensive hormonal panel, lipids, CBC, CMP
Men on long-term DHEA: annual PSA
Women on long-term DHEA: annual breast exam, pelvic exam, mammography per schedule
Continue only if benefits are clearly present and side effects absent

Formulation considerations for beginners:

Oral capsules/tablets: standard form, convenient, 25mg typical starting tablet (can be cut for women)
Micronized DHEA: better absorption; preferred when available
Topical/transdermal DHEA cream (1-2% cream, specialty compounding pharmacies): avoids first-pass metabolism; more physiological profile; often preferred by functional medicine practitioners. Apply to upper inner thigh or abdomen daily. Dosing typically 5-10mg per application in women, 10-25mg in men.
Sublingual DHEA: rapid absorption; some practitioners prefer for specific applications
Vaginal DHEA (Intrarosa 6.5mg, FDA-approved): prescription form for vaginal atrophy, minimal systemic absorption. Different indication than systemic DHEA.

When NOT to continue in Beginner Protocol:

No clear subjective benefit after 8-12 weeks at appropriate dose
Significant side effects (acne, hirsutism, sleep disruption, mood changes)
Concerning lab changes (supraphysiological hormone levels, abnormal lipid changes)
New diagnosis that contraindicates DHEA (hormone-sensitive cancer, pregnancy, etc.)
Inability to commit to monitoring

Red flags during Beginner Protocol — stop and consult physician:

Breast mass, unusual lump, or tenderness in either sex
Prostate symptoms in men (urinary changes, pelvic discomfort)
Unusual or persistent bleeding
Severe mood changes
Development of hirsutism or voice changes that don't resolve with discontinuation
Any concern about hormone-sensitive disease

Cost: standard oral DHEA supplements run $10-20/month at 25mg/day from reputable brands. Compounded transdermal is typically $30-50/month. Pharmaceutical-grade prasterone is significantly more expensive and usually prescription-only.

Standard

The Intermediate Protocol addresses specific clinical indications where DHEA has stronger evidence: midlife-onset depression, IVF poor responders, post-menopausal genitourinary symptoms, and adrenal insufficiency support.

Midlife-onset depression protocol (based on Schmidt 2005, and related evidence):

Population: adults 40-65 with major depressive disorder, particularly those with low DHEA-S at baseline
Dose: DHEA 90-300mg/day oral, typically split as 30-100mg TID
Duration: 6-8 week trial to assess response
Co-management: should be adjunctive to standard depression care (therapy, lifestyle interventions); can be used alongside antidepressant medications with psychiatric coordination
Monitoring:
Baseline: comprehensive hormonal panel, metabolic labs, depression rating scales (HAM-D or PHQ-9)
2-4 weeks: initial response assessment, side effect screen
6-8 weeks: primary outcome assessment
Dose titration: start at 90mg/day and increase by 30-60mg every 1-2 weeks up to 300mg as tolerated until response or side effects
Side effect management: higher doses increase androgenic/estrogenic effects; discontinue or reduce if significant symptoms
Response: 50% of responders in clinical trials met response criteria; if no response after 6-8 weeks at full dose, discontinue
Not for: bipolar depression (may trigger hypomania), psychotic depression, hormone-sensitive cancer history

IVF poor responder protocol (based on Wiser 2010):

Population: women with diminished ovarian reserve (DOR), poor responder phenotype, or previous IVF cycle failure
Dose: DHEA 75mg/day (25mg TID) oral
Duration: minimum 3 months before stimulation cycle; some protocols use 4-6 months
Co-management: reproductive endocrinology supervision; integration with stimulation protocol
Monitoring:
Baseline: DHEA-S, AMH, FSH, estradiol, ovarian antral follicle count
6-12 weeks: labs to confirm DHEA-S rise
Just before stimulation: baseline labs
Adjustments: dose reduction if significant androgenic side effects (hirsutism, acne); if substantial symptoms, consider alternative approach
Discontinuation: typically continued through stimulation phase, discontinued around ovulation trigger or early in pregnancy
Evidence note: evidence is moderate with mixed results across trials; reasonable trial in poor responder patients but not uniformly adopted

Post-menopausal vaginal atrophy and genitourinary symptoms:

For systemic treatment in post-menopausal women with comprehensive symptoms:

Oral DHEA 25-50mg/day AM for 3-6 months with symptom reassessment
Often combined with topical vaginal estrogen (if not contraindicated) or topical DHEA
Labrie intracrinology framework supports peripheral conversion providing tissue-specific effects

For targeted vaginal treatment:

Intravaginal prasterone (Intrarosa) 6.5mg daily (prescription, FDA-approved 2016)
Minimal systemic absorption; primarily local effect
No age limits for this application
Typical response within 4-12 weeks
May be continued long-term if benefits persist

Addison's disease / primary adrenal insufficiency replacement:

Women: DHEA 25-50mg/day AM, typically lifelong
Men: variable; may or may not benefit, typically not prescribed
Combined with glucocorticoid (hydrocortisone) and mineralocorticoid (fludrocortisone) replacement
Endocrinology supervision essential
Monitor DHEA-S (target upper half of reference), androgens, estradiol
Dose adjustment based on side effects and response

Secondary adrenal insufficiency with cortisol replacement:

Similar protocol; DHEA often added for women
25-50mg AM
Endocrinology supervision

Systemic lupus erythematosus (SLE) adjunctive:

Dose: DHEA 200mg/day (may allow glucocorticoid dose reduction)
Rheumatology supervision required
Monitor disease activity, SLEDAI score, autoimmune markers, lipid panel
Not all patients respond; typical trial 3-6 months
Dose reduction if androgenic side effects limit tolerability

Schizophrenia adjunctive (specific subpopulations):

Dose: DHEA 100-200mg/day
Added to standard antipsychotic therapy
Psychiatric supervision required
May improve negative symptoms and cognitive deficits in responders

Transdermal/topical protocol (alternative to oral):

1-2% DHEA cream from compounding pharmacy
Apply 5-10mg (women) or 15-25mg (men) to upper inner thigh or abdomen daily
More physiological time-release profile
Avoids first-pass hepatic metabolism
May be preferred for women sensitive to oral hormonal effects

Combination protocols for "hormonal optimization":

DHEA 25-50mg AM
Pregnenolone 10-30mg AM
Vitamin D 2,000-5,000 IU
Magnesium glycinate 300-400mg
Zinc 15-25mg
Omega-3 fatty acids 1,000-2,000mg
Ashwagandha 300-600mg KSM-66
Lifestyle optimization (exercise, sleep, stress management)

Monitoring schedule for Intermediate Protocol:

Before starting: comprehensive hormonal panel (DHEA-S, testosterone, estradiol, SHBG, LH/FSH where relevant), lipid panel, CBC, CMP, PSA (men), mammogram status (women)
4-6 weeks: initial response check, side effect screen, selected hormone levels
12 weeks: comprehensive labs, clinical assessment
Every 6-12 months thereafter: comprehensive panel
Annual: age-appropriate cancer screening (mammogram, PSA, pelvic exam, colonoscopy per guidelines)

When to stop:

Clear side effects not resolved with dose reduction
Development of hormone-sensitive cancer
Significant lab abnormalities
No clear benefit after adequate trial (typically 3 months)
Patient preference

Dose ceiling in Intermediate Protocol: 300mg/day for depression trials, 200mg/day for other indications, 75mg/day for IVF, 50mg/day for general replacement. Doses above these are Advanced Protocol territory.

Advanced

The Advanced Protocol covers high-dose therapeutic use, complex multi-hormone replacement scenarios, and specialized contexts — all requiring physician supervision and appropriate clinical rationale.

High-dose therapeutic depression trial (refractory cases, under psychiatric supervision):

Dose: DHEA 300-450mg/day (the upper range of Schmidt 2005 study)
Duration: 6-8 week trial
Monitoring: baseline and periodic depression rating scales, comprehensive hormonal panel, liver function, lipid panel, metabolic markers
Side effect management: expect significant androgenic/estrogenic effects at these doses; women may require discontinuation for acne/hirsutism
Co-management: integrated with standard depression treatment; psychiatric collaboration essential
Not first-line: reserved for cases refractory to conventional antidepressants and failing lower-dose DHEA trial

Lupus high-dose adjunctive (under rheumatology):

Dose: DHEA 200mg/day
Clinical context: allows glucocorticoid sparing; may reduce disease activity
Monitoring: SLEDAI, autoimmune markers, glucocorticoid dose adjustment
Duration: typically continued as long as benefit is evident and side effects tolerable

Comprehensive hormone replacement in multi-axis deficiency:

For patients with combined adrenal insufficiency + hypogonadism or other multi-hormonal insufficiency
Integrated replacement: glucocorticoid (hydrocortisone) + mineralocorticoid (fludrocortisone) + DHEA + testosterone or estrogen as appropriate
Endocrinology coordination essential
Individualized dose titration based on response and monitoring

Peri-surgical and critical illness adjunctive:

Research context: some critical care protocols have explored DHEA during sepsis and critical illness for adrenal support
Not standard care; investigational
Clinical coordination required

Specialized IVF protocols:

Extended DHEA trials (4-6 months preceding stimulation) for repeatedly-failed IVF cycles
Sometimes combined with growth hormone, CoQ10, or other ovarian support compounds
Reproductive endocrinology specialization

Transdermal/topical therapy for advanced users:

Compounded transdermal DHEA 2-5% cream
Allows fine dose titration and avoids first-pass metabolism
Particularly useful for women with oral GI intolerance or variable absorption issues
Compounding pharmacy essential

Sublingual DHEA for specific applications:

Rapid absorption; used in some clinical protocols for targeted timing effects
Less common than oral or transdermal

Monitoring intensity for Advanced Protocol:

Every 4-6 weeks initially: clinical assessment, symptom monitoring, side effect screen
Every 3 months: comprehensive hormonal panel (DHEA-S, free and total testosterone, estradiol, SHBG, LH, FSH, cortisol, thyroid)
Every 6 months: lipid panel, CBC, CMP, LFT, PSA (men), breast exam (women)
Annual: mammography (women), prostate exam (men), colorectal screening per guidelines

Contraindications strengthened at high doses:

Any history of hormone-sensitive cancer
Active prostate nodule or elevated PSA
Undiagnosed breast mass or lump
Severe hepatic impairment
Active psychotic depression or bipolar disorder in manic phase
Pregnancy or pregnancy planning
Children and adolescents
Competitive athletes

Drug interactions requiring close management at high doses:

Insulin and diabetes medications: potential glucose effects
Antihypertensives: variable BP effects
Anticoagulants: INR monitoring
Testosterone replacement: risk of supraphysiological androgens
Estrogen replacement: total estrogen management
SERM therapy (tamoxifen, raloxifene): avoid combination
Aromatase inhibitors: contraindicated combination
5α-reductase inhibitors (finasteride): may blunt their effect

Cost considerations at high doses:

Oral DHEA 300mg/day from reputable brands: $50-150/month
Compounded transdermal at therapeutic doses: $100-300/month
Pharmaceutical prasterone (Fidelin, Prastera where available): variable, often expensive
Vaginal prasterone (Intrarosa): specialty pharmacy

Extended high-dose use considerations:

Long-term safety data beyond 2-4 years at doses >100mg/day is limited
Theoretical concerns about hormone-sensitive cancer development with chronic high-dose use
Receptor and enzyme adaptation may occur with long-term use
Periodic reassessment of ongoing need and response is essential

Alternative approaches for specific indications:

For vaginal atrophy: intravaginal prasterone (Intrarosa) or topical estrogen — more targeted and lower systemic exposure
For adrenal insufficiency: standard glucocorticoid/mineralocorticoid replacement is primary; DHEA is adjunctive
For depression: lifestyle, therapy, conventional antidepressants are first-line; DHEA is adjunctive
For low libido / sexual dysfunction: comprehensive workup before hormonal interventions

Stopping Advanced Protocol:

Gradual taper reasonable for users on long-term high-dose DHEA (though not required for safety)
Discontinuation rebound not typically severe
Monitor for re-emergence of symptoms that prompted treatment

Key Advanced Protocol principle: high-dose DHEA therapy has clear indications in specific clinical contexts but warrants comprehensive medical management. Self-directed high-dose use is inappropriate given the hormonal potency, side effect profile, and theoretical cancer considerations. The opportunity for benefit in appropriate clinical indications is real; the requirement for physician oversight is not optional for these dose ranges.

Commonly Stacked With

DHEA stacking requires care due to its hormonal potency and potential for compounding androgenic or estrogenic effects with other hormonal supplements or medications. The primary stacking principle: DHEA is a hormone, not a typical supplement, and should be integrated into overall hormonal-support strategy with attention to baseline endocrine status, sex-specific considerations, and total hormonal exposure.

DHEA + Pregnenolone (if available in your pharmacy): pregnenolone is the precursor to DHEA (and to cortisol and progesterone). Some practitioners use both together for comprehensive adrenal support in documented adrenal insufficiency or chronic stress states. Typical dosing: pregnenolone 10-50mg/day + DHEA 25-50mg/day. This combination broadens hormone precursor support but should not be undertaken without clear indication given that both are hormones. Coordinate with endocrinology or functional medicine physician.

DHEA + Vitamin D (2,000-5,000 IU/day): complementary hormonal-support framework. Vitamin D is itself a hormone with systemic effects; adequate vitamin D supports overall endocrine function. No direct interaction but commonly combined in hormonal-health protocols.

DHEA + Ashwagandha (300-600mg KSM-66): complementary adrenal and stress support. Ashwagandha may modestly support endogenous DHEA production, reduce cortisol, and balance HPA axis; DHEA provides direct hormone precursor. Together they address both regulatory and substrate aspects of adrenal health. Common pairing for midlife hormonal optimization.

DHEA + Magnesium + Zinc: complementary foundation minerals for hormonal synthesis and function. No direct interaction but comprehensive hormonal-support stacks typically include these.

DHEA + Omega-3 fatty acids (DHA + EPA 1,000-2,000mg): complementary anti-inflammatory and cardiovascular support. No direct interaction.

DHEA + Rhodiola Rosea (300-600mg): complementary HPA-axis adaptogen + hormone precursor. Common pairing.

DHEA + Panax Ginseng (200-400mg): complementary; no direct interaction.

DHEA + Tongkat Ali (200-400mg) and/or Fadogia Agrestis (600mg): for men pursuing testosterone optimization — these herbs may support endogenous testosterone, and DHEA provides substrate. However, combining hormone-affecting herbs with DHEA warrants care — risk of supraphysiological androgen/estrogen levels. Monitor with periodic testosterone, estradiol, and PSA testing. Not for men on TRT or with prostate issues.

DHEA + [Testosterone Replacement Therapy (TRT)]: generally redundant and potentially excessive. TRT provides direct testosterone; adding DHEA adds more androgen precursor, risking supraphysiological levels. Coordinate with TRT prescriber; usually DHEA is not needed alongside TRT.

DHEA + Estrogen replacement therapy (HRT): may add to total estrogen exposure; coordinate with prescribing gynecologist. For post-menopausal women on systemic HRT, DHEA may not be necessary except for specific indications.

DHEA + Cholesterol-lowering medications (statins): statins reduce overall steroid hormone synthesis by inhibiting HMG-CoA reductase (the precursor to steroid production). DHEA supplementation can partially offset this effect. Generally safe combination; monitor lipid panel.

Stacks to avoid or approach cautiously:

DHEA + Anabolic-androgenic steroids (AAS): supraphysiological androgen exposure; not recommended without medical supervision.
DHEA + SERM medications (tamoxifen, raloxifene): theoretical interaction; avoid combining outside specific oncology context.
DHEA + Aromatase inhibitors: DHEA provides aromatase substrate that inhibitors block; theoretical interaction. Avoid unless specifically directed.
DHEA + 5α-reductase inhibitors (finasteride, dutasteride): DHEA provides the substrate these drugs partially block. May reduce clinical effect. Discuss with prescriber.
DHEA + Growth hormone or GH secretagogues (CJC-1295, sermorelin, ipamorelin): both hormonal interventions; comprehensive monitoring recommended.
DHEA + High-dose caffeine or stimulants: DHEA has mild alerting effects via GABA-A antagonism; combining with high stimulants may produce anxiety, insomnia, or sleep disruption. Moderate.

Timing considerations:

Morning dosing preferred: DHEA's alerting effects (GABA-A antagonism) and the natural circadian rhythm of adrenal hormone secretion favor morning dosing.
Split dosing (morning + early afternoon) for doses above 50mg to avoid evening levels that disrupt sleep.
Avoid late evening dosing — can disrupt sleep onset and reduce sleep quality.

Monitoring for combination stacks:

Baseline labs: DHEA-S, total and free testosterone, estradiol, CBC, CMP, lipid panel, PSA (men), breast exam (women)
Follow-up labs: 6-12 weeks after initiation for hormone levels, metabolic parameters
Annual: comprehensive hormonal and metabolic panel
Men on long-term DHEA: annual PSA, testicular/prostate exam
Women on long-term DHEA: annual breast exam, pelvic exam; consider mammography per standard screening

Sex-specific stacking considerations:

Men on DHEA: typically lower doses (25mg/day) to avoid excessive androgen or estrogen exposure. Monitor estradiol (rising estradiol in men suggests excessive aromatization and may warrant dose reduction). Combine with zinc (supports testosterone synthesis) and adequate omega-3 (anti-inflammatory). Avoid combining with herbal aromatase inhibitors without medical guidance.

Women on DHEA: more sensitive to androgenic effects; monitor for acne, hirsutism. Low doses (5-25mg/day) typically sufficient. May combine with phytoestrogens (Schisandra, etc.) for comprehensive hormonal support. Pre-menopausal women should coordinate with gynecology given potential menstrual cycle effects.

Elderly: dose reduction often appropriate given reduced metabolic clearance and age-related hormone sensitivity.

Pregnancy/lactation: DHEA contraindicated except in specific reproductive endocrinology protocols.

The "hormonal optimization" comprehensive protocol for adults with confirmed low DHEA-S:

DHEA 25-50mg AM + Pregnenolone 10-30mg AM
Ashwagandha 300-600mg KSM-66 (morning or evening)
Vitamin D 2,000-5,000 IU/day (dose to maintain 25-OH-D 40-60 ng/mL)
Magnesium glycinate 300-400mg elemental
Zinc 15-25mg
Omega-3 fatty acids 1,000-2,000mg EPA+DHA
Regular exercise (both aerobic and resistance)
Adequate sleep and stress management
Physician monitoring every 6-12 months

The practical stacking synthesis: DHEA is the most powerful single compound in a hormonal-support stack, and it should be used at the lowest effective dose for clear indication. Foundation supplements (minerals, omega-3, vitamin D) support overall hormonal machinery. Additional hormone precursors (pregnenolone) broaden support. Adaptogenic herbs modulate stress/cortisol axis. Combining multiple hormone-affecting supplements warrants clinical monitoring rather than self-directed experimentation.

Side Effects & Safety

**DHEA has a well-characterized side effect profile that is largely predictable based on its androgenic and estrogenic conversion**. Effects are dose-dependent, sex-dependent, and individual-variable based on body composition, age, and enzyme expression. **Androgenic side effects (more prominent in women given lower baseline androgens)**: - **Acne**: facial and back acne are common at doses above 25-50mg in women, related to increased DHT conversion in skin. Usually mild and reversible with dose reduction. - **Hirsutism**: increased facial, chin, chest, or abdominal hair growth with chronic higher-dose use in women. May be more persistent than acne after discontinuation. - **Male-pattern scalp hair thinning**: androgen-sensitive individuals may experience worsening of androgenic alopecia with higher DHEA doses. Both sexes potentially affected. - **Voice deepening**: rare but reported with very high doses (100mg+) in women over extended periods; may be partially irreversible. - **Oily skin**: common, generally mild, reversible with dose reduction. - **Irregular menstrual bleeding**: some women experience cycle changes, spotting, or menstrual irregularities on DHEA. - **Clitoromegaly**: very rare, with prolonged high-dose use in women. **Estrogenic side effects (more prominent in men, particularly those with high body fat for aromatase activity)**: - **Gynecomastia**: male breast tissue development from conversion of DHEA-derived androgens to estradiol via aromatase. More likely in men with higher body fat percentage or genetic predisposition. May require dose reduction or discontinuation. - **Water retention and edema**: modest, usually reversible. - **Nipple tenderness**: common early sign of estrogenic activity in men. **Mood and psychiatric effects**: - **Insomnia or sleep disruption**: the alerting/anti-GABA effects of DHEA can disrupt sleep, particularly at higher doses or with evening dosing. Morning dosing and lower doses minimize this. - **Anxiety or irritability**: some users report increased anxiety, restlessness, or irritability on DHEA. May be dose-related. - **Paradoxical depression**: rare but reported, particularly with higher doses in susceptible individuals. - **Hypomania**: rare; reported particularly in individuals with bipolar-spectrum vulnerability. DHEA should be used cautiously or avoided in bipolar disorder. - **Aggression**: mild increases in aggression have been reported at high doses, particularly in men. **Metabolic effects**: - **Modest insulin sensitivity changes**: generally favorable in some populations, but high doses may produce adverse metabolic effects in susceptible individuals. - **Cholesterol changes**: modest effects on HDL (sometimes reduced, particularly at higher doses) and LDL. Monitoring reasonable with long-term high-dose use. - **Liver function**: uncommon but high-dose chronic DHEA can modestly elevate liver enzymes; LFT monitoring reasonable. **Cardiovascular effects**: - **Blood pressure**: variable, usually neutral; occasional reports of modest increases. - **Palpitations**: uncommon, usually dose-related. **Hormone-sensitive cancer risk**: - **Theoretical concern about hormone-sensitive cancers**: DHEA's conversion to androgens and estrogens creates theoretical concerns for breast, prostate, endometrial, and other hormone-sensitive cancers. Individuals with these cancers or high-risk family histories should avoid DHEA unless specifically directed by oncology. - **Prostate**: for men with active or prior prostate cancer, DHEA-derived androgen conversion is of particular concern. Avoid in these populations. - **Breast cancer**: similarly, estrogen conversion creates concern for breast cancer patients or high-risk women. **Drug interactions**: - **Insulin and diabetes medications**: DHEA modestly affects insulin sensitivity; monitor glucose when initiating. - **Antihypertensive medications**: variable effects on BP; monitor. - **Warfarin and anticoagulants**: isolated reports of INR changes; monitor. - **Corticosteroids**: DHEA modestly opposes glucocorticoid effects at some tissue levels; generally not clinically significant. - **Testosterone replacement therapy**: adding DHEA to TRT is generally redundant and increases risk of supraphysiological testosterone levels; coordinate with prescriber. - **Estrogen replacement therapy**: DHEA adds to overall estrogen exposure; review total hormonal picture. - **Tamoxifen and aromatase inhibitors**: DHEA interferes with the purpose of these anti-estrogen therapies; avoid combining without specific oncology guidance. - **Finasteride or dutasteride**: DHEA increases androgen substrate that these medications partially block; may reduce their clinical effect. Discuss with prescriber. - **Lithium**: theoretical; limited data on interaction. - **Antipsychotics**: DHEA has been used as schizophrenia adjunct; otherwise neutral interaction. - **Anticonvulsants**: some anticonvulsants affect steroid metabolism; coordinate with neurology. **Pregnancy and lactation**: - **Pregnancy**: DHEA supplementation during pregnancy is contraindicated outside specific reproductive endocrinology protocols (IVF contexts use only until pregnancy is established). Fetal androgen exposure from maternal DHEA supplementation is a serious concern. - **Lactation**: contraindicated; hormonal effects on nursing infant. **Pediatric use**: - **Not recommended except in specific pediatric endocrinology contexts** (congenital adrenal hyperplasia, specific deficiency states). - Premature puberty concerns with any pediatric sex steroid exposure. - Children found with adult DHEA supplements should be evaluated for hormone exposure concerns. **Athletic competition**: - **Banned substance**: DHEA is on the WADA Prohibited List, NCAA list, and most professional sports league prohibited substance lists. Competitive athletes must avoid all forms of DHEA. **Long-term safety**: - Long-term safety data beyond 2-4 years is limited for doses >50mg/day - Multi-year use at 25-50mg/day for adrenal insufficiency has acceptable long-term safety profile - Unknown long-term effects on hormone-sensitive cancer development or progression with chronic high-dose use - Periodic monitoring of hormonal panel, metabolic parameters, and breast/prostate health reasonable for long-term users **Quality control concerns with OTC DHEA**: - **Product quality varies widely**: multiple analyses have documented OTC DHEA products containing 0-150% of label claim. Prefer pharmaceutical-grade (Intrarosa, Fidelin, Prastera) where available, or reputable brands with third-party testing (USP, NSF, ConsumerLab). - Some OTC products contain DHEA analogs or contaminants rather than pure DHEA. **Overdose**: - No documented serious acute toxicity at single doses up to 1,600mg - Chronic daily doses above 200mg produce substantial androgenic/estrogenic side effects but not immediate serious toxicity - Long-term supraphysiological doses theoretically concerning for hormone-sensitive tissue effects **When to stop DHEA and seek medical evaluation**: - Development of significant acne, hirsutism, voice changes, or other androgenic symptoms not resolved with dose reduction - Gynecomastia development in men - Mood changes (significant depression, anxiety, hypomania) - Breast lumps or unusual masses - Prostate symptoms (urinary changes, discomfort) - Abnormal menstrual bleeding - Unexplained fatigue, weight changes, or other endocrine symptoms - Pregnancy or pregnancy planning - New diagnosis of hormone-sensitive cancer or increased family history concern - Any abnormal lab values on routine monitoring **Key safety summary**: DHEA produces predictable androgenic and estrogenic side effects at higher doses, with sex-specific patterns (women more androgenic-sensitive, men more estrogenic-sensitive via aromatization). Low-dose DHEA (25mg/day) for appropriate clinical indications has a favorable safety profile; higher doses (100-200mg+) produce notable side effects. Hormone-sensitive cancer history is a strong contraindication. Pregnancy/lactation are absolute contraindications outside specialized reproductive protocols. Quality control with OTC products is a meaningful concern.

Contraindications

**DHEA has multiple important contraindications and requires clinical caution across multiple populations** given its hormonal potency and conversion to androgens and estrogens. **Absolute or strong relative contraindications**: **Hormone-sensitive cancers (absolute contraindication)**: - **Breast cancer (active, remission, or high-risk family history)**: DHEA converts to estradiol via aromatase; estradiol is the primary driver of ER+ breast cancer. Avoid DHEA in any woman with active breast cancer, history of breast cancer, high-risk family history, or known BRCA mutations. - **Prostate cancer (active, remission, or elevated PSA)**: DHEA converts to testosterone and DHT; these androgens are primary drivers of prostate cancer. Avoid DHEA in men with active prostate cancer, history of prostate cancer, elevated PSA (>4 ng/mL or concerning trajectory), or prostate nodule. - **Endometrial cancer**: estrogenic conversion is concerning. Avoid. - **Ovarian cancer**: hormone-sensitive subtypes are concerning. Avoid unless specifically directed by oncology. - **Hormone-sensitive tumors** (generally): discuss with oncology before considering DHEA. **Pregnancy and lactation (absolute contraindication)**: - **Pregnancy**: DHEA supplementation during pregnancy is contraindicated outside specialized reproductive endocrinology protocols (IVF contexts where DHEA is used only until pregnancy is established, then discontinued). Fetal androgen exposure is a serious concern, particularly for female fetal development. - **Lactation**: DHEA passes into breast milk; hormonal effects on nursing infants are concerning. Avoid. **Pediatric use (strong relative contraindication)**: - DHEA is not appropriate for children and adolescents outside specific pediatric endocrinology indications (congenital adrenal hyperplasia, specific adrenal deficiency) - Premature puberty concerns with any pediatric sex steroid supplementation - Children who accidentally ingest adult DHEA supplements should be evaluated for hormonal exposure **Major relative contraindications warranting specific caution**: **Bipolar disorder**: - Rare reports of hypomania or mania triggered by DHEA, particularly at higher doses - Avoid in active bipolar disorder unless under psychiatric supervision - Caution in bipolar spectrum disorders **Untreated or severe depression with suicidality**: - DHEA can paradoxically worsen depression in some individuals - Not first-line; use only under psychiatric supervision if at all **Polycystic ovary syndrome (PCOS) with androgenic symptoms**: - PCOS patients already have elevated androgen symptoms (hirsutism, acne, alopecia) - Adding DHEA often worsens these symptoms - Generally avoid in active PCOS unless reproductive endocrinology directs **Severe liver disease or severe hepatic impairment**: - DHEA is extensively hepatically metabolized - Severe cirrhosis, hepatic encephalopathy, or acute liver failure warrants avoidance - Moderate liver impairment warrants dose reduction and caution **Severe renal impairment**: - Moderate reduction in dose may be prudent in severe CKD (CrCl <30 mL/min) **Cardiovascular disease, uncontrolled hypertension**: - Variable effects on BP and metabolic parameters - Monitor carefully if starting - Not absolute contraindication but caution warranted **Diabetes, particularly poorly controlled**: - Variable effects on insulin sensitivity - Monitor glucose when starting **Active androgenic alopecia, hirsutism, or voice changes**: - DHEA will likely worsen these conditions - Discuss with dermatology or endocrinology **Competitive athletics**: - DHEA is on the WADA Prohibited List, NCAA banned substance list, and most professional sports league lists - Athletes competing in drug-tested sports must avoid DHEA **Drug interactions requiring coordination**: **Insulin and diabetes medications**: monitor blood glucose when starting; may require medication adjustment. **Antihypertensive medications**: variable effects on BP; monitor. **Warfarin and anticoagulants**: isolated reports of INR changes; monitor particularly in the first month of DHEA initiation or dose change. **Testosterone replacement therapy (TRT)**: adding DHEA to TRT is usually redundant and risks supraphysiological testosterone. Coordinate with TRT prescriber. **Estrogen replacement therapy (HRT)**: DHEA adds to total estrogen exposure via aromatization. Review total hormonal picture. **SERM medications (tamoxifen, raloxifene)**: DHEA interferes with the anti-estrogen purpose; avoid combining without oncology guidance. **Aromatase inhibitors (anastrozole, letrozole, exemestane)**: DHEA provides substrate for aromatase; combining defeats the purpose. Avoid unless specifically directed. **5α-reductase inhibitors (finasteride, dutasteride)**: DHEA provides DHT substrate; may blunt clinical effect. Discuss with prescriber. **Corticosteroids**: DHEA modestly opposes glucocorticoid effects; generally not clinically significant at standard doses. **Antipsychotics**: DHEA has been studied as schizophrenia adjunct; otherwise neutral interaction. **Lithium**: theoretical interaction; limited clinical data. **Anticonvulsants affecting steroid metabolism** (phenytoin, carbamazepine, phenobarbital): may alter DHEA metabolism; monitor response. **Oral contraceptives**: effects on overall hormonal balance; discuss with gynecology. **MAO inhibitors**: theoretical concerns about sympathomimetic effects from increased androgen exposure; caution. **Alcohol**: no direct pharmacokinetic interaction but both affect hepatic metabolism; moderate use. **Thyroid medications**: generally neutral interaction. **When to stop DHEA and seek medical evaluation**: - Breast lump, unusual mass, or tenderness in either sex - Prostate symptoms (urinary changes, pelvic discomfort) - Unusual bleeding - Severe mood changes (depression, hypomania, severe anxiety) - Development of significant androgenic symptoms not resolved with dose reduction (persistent acne, hirsutism, voice changes, male-pattern hair loss) - Gynecomastia development in men - Breakthrough bleeding or significant menstrual changes in women - Pregnancy or pregnancy planning - New diagnosis of hormone-sensitive cancer - New major medical diagnosis warranting medication review - Abnormal hormonal lab trends (supraphysiological levels, concerning androgen/estrogen ratios) - Abnormal liver function tests - Any concerning cardiovascular, metabolic, or mental health changes **Special populations and considerations**: **Menopausal transition (perimenopause)**: - Variable hormonal effects; individual response unpredictable - Caution with symptomatic perimenopausal women — DHEA may disrupt natural fluctuations - Discuss with gynecology **Post-menopause with HRT considerations**: - DHEA may integrate with or complicate standard HRT - Discuss total hormonal picture with gynecology - Target population for potential benefit but requires individualized assessment **Low libido and sexual dysfunction**: - Multifactorial conditions requiring complete workup - DHEA is one of multiple possible interventions, not first-line - Endocrinology or sexual medicine evaluation recommended **Chronic fatigue states**: - DHEA often tried but rarely the full answer - Comprehensive medical evaluation is primary - "Adrenal fatigue" is not medically validated; true adrenal insufficiency requires specific diagnosis **Obesity**: - More aromatase activity in adipose tissue; men with higher body fat may experience greater estrogenic conversion from DHEA - Monitor estradiol in obese men on DHEA - Weight loss may reduce DHEA-related estrogenic effects **Elderly**: - Generally lower doses appropriate - More careful monitoring of hormonal, cardiovascular, and metabolic parameters - More frequent drug interaction reviews **Athletes and fitness contexts**: - Competitive athletes must avoid DHEA (banned substance) - Recreational fitness users should weigh androgenic side effects vs perceived performance benefits - Evidence for performance enhancement in non-deficient individuals is weak **Transgender populations**: - Complex hormonal considerations; typically coordinated with endocrinology - DHEA not standard in transition-related hormone therapy but may be used for specific indications **Long-term safety summary**: - Multi-year safety data beyond 2-4 years at doses >50mg/day is limited - Theoretical hormone-sensitive cancer concerns with chronic high-dose use - Periodic reassessment of ongoing need and response is essential - Lower doses (25mg/day) for appropriate indications have more favorable long-term safety profile **Final summary**: DHEA is a potent hormone with clear contraindications (hormone-sensitive cancer, pregnancy, pediatric use), significant relative contraindications (bipolar, PCOS, severe liver disease, competitive athletics), and meaningful drug interactions. Its use should be driven by clinical indication (confirmed low DHEA-S, specific conditions with evidence) rather than general anti-aging claims. Physician oversight is particularly valuable given the hormonal potency and need for individualization. This is general educational content, not individualized medical advice. Anyone considering DHEA supplementation should consult a physician familiar with hormonal therapies, obtain appropriate baseline labs, and commit to ongoing monitoring.

Check interactions with the Interaction Checker →

Additional Notes

Dosing DHEA requires individualization based on sex, age, indication, baseline DHEA-S, and response — no single dose is appropriate for all users.

Standard dose ranges by indication and population:

Women, general supplementation for low DHEA-S:

Starting dose: 5mg/day oral morning
Typical effective dose: 10-25mg/day
Target DHEA-S: upper half of age-appropriate reference range
Higher doses (50-100mg) for specific indications (IVF poor responder, depression) under medical supervision

Men, general supplementation for low DHEA-S:

Starting dose: 25mg/day oral morning
Typical effective dose: 25-50mg/day
Target DHEA-S: upper half of age-appropriate reference range
Higher doses (75-100mg+) rarely needed; may increase estrogenic conversion

Clinical indications with specific dose ranges:

Primary adrenal insufficiency (Addison's): women 25-50mg/day; men often not prescribed or 25mg/day
Vaginal atrophy systemic: 25-50mg/day oral; topical 6.5mg vaginal prasterone (Intrarosa)
Midlife-onset depression: 90-300mg/day (divided TID)
IVF poor responder: 75mg/day (25mg TID) for 3+ months
Systemic lupus adjunctive: 200mg/day
Schizophrenia adjunctive: 100-200mg/day
Age-related cognitive/physical complaints: evidence does not strongly support use; not recommended based on Nair 2006

Timing:

Morning dosing: strongly preferred to avoid sleep disruption and to align with circadian adrenal rhythm
Split dosing (morning + early afternoon) for doses above 50mg/day
Avoid late afternoon/evening dosing: DHEA's mild alerting effects can interfere with sleep
With or without food: absorption similar; with food reduces any GI upset

Formulation options:

Oral capsules/tablets: standard, convenient, accurate dosing. Most common. Choose micronized DHEA when available (better absorption).

Sublingual DHEA: faster absorption, may require lower dose for equivalent plasma levels. Less common; some clinical applications.

Transdermal cream (compounded 1-2% or 2-5%): avoids first-pass hepatic metabolism, more physiological delivery, smoother plasma profile. Apply 1mL (providing 5-25mg depending on concentration) to thin skin area (upper inner thigh, abdomen). Preferred by many functional medicine practitioners. Requires compounding pharmacy.

Intravaginal prasterone (Intrarosa 6.5mg): FDA-approved prescription for vaginal atrophy; minimal systemic absorption. Different indication than systemic DHEA. Daily application.

Intramuscular injectable DHEA: not common; specialized clinical use.

Comparison of DHEA forms:

DHEA (3β-hydroxy-5-androsten-17-one): standard, used in most clinical trials
DHEA-S (sulfated): longer half-life but less efficient CNS penetration; less commonly supplemented; the body efficiently interconverts DHEA and DHEA-S
7-keto-DHEA: a DHEA metabolite marketed as providing benefits without converting to sex steroids; claims are partly supported but evidence is less robust than for plain DHEA

Lab monitoring:

Baseline DHEA-S: reference ranges vary by age and sex
- Young adults (20-30): 200-500 μg/dL
- Middle-aged (40-50): 100-300 μg/dL
- Older adults (60+): 50-200 μg/dL
Target on supplementation: upper half of age-appropriate reference, not supraphysiological
Additional hormonal labs if on long-term DHEA: testosterone (total, free), estradiol, SHBG, LH, FSH, cortisol, thyroid panel
Sex steroid ratios: total testosterone:estradiol in men (favor testosterone dominance); total testosterone in women (avoid virilization)
Follow-up timing: 6-12 weeks after initiation, then every 6-12 months if stable

Dose titration approach:

Start at conservative sex-appropriate dose
Monitor for 4-6 weeks for subjective effects and side effects
Obtain follow-up DHEA-S at 6-12 weeks
Adjust dose based on lab results and clinical response
Re-evaluate every 6-12 months long-term

Avoiding supraphysiological exposure:

If DHEA-S rises above age-appropriate reference range on supplementation, reduce dose
If testosterone or estradiol rise meaningfully above baseline (particularly >20% increase in men's estradiol), reduce DHEA
Side effects (acne, hirsutism, gynecomastia) signal excessive conversion — reduce dose

Drug holidays and cycling:

Periodic breaks (1-2 weeks off every 6-12 months) reasonable to reassess ongoing benefit
Not essential for safety; benefits-check purpose
No rebound concerns requiring taper

Storage:

Room temperature (15-25°C / 59-77°F)
Tightly-sealed original container
Protected from direct sunlight, heat, and humidity
Typical shelf life 2-3 years from manufacture
Transdermal creams: check for separation or oxidation; typically good for 6-12 months after opening

Product quality considerations:

OTC DHEA quality varies: multiple analyses have documented content ranging 0-150% of label claim
Prefer: products with USP, NSF, or ConsumerLab third-party testing
Reputable brands (not endorsements): Pure Encapsulations, Thorne, Nature's Way, Douglas Laboratories, Life Extension, Double Wood Supplements, Jarrow Formulas
Pharmaceutical grade: Fidelin, Prastera (where available internationally); Intrarosa (prescription, vaginal)
Avoid: bargain-price products from unknown sources, products with DHEA "blends" or unclear labeling

Overdose:

No documented serious acute toxicity at single doses up to 1,600mg in clinical research
Chronic daily doses above 200mg produce significant side effects but not immediate serious toxicity
Long-term supraphysiological dosing has theoretical hormone-sensitive tissue concerns

Sex-specific dosing summary:

Women generally require much lower doses than men (baseline androgens are 10-20× lower)
Women: typically 5-25mg is adequate for general supplementation; exceptions for specific high-dose indications
Men: typically 25-50mg is adequate; higher doses rarely provide additional benefit and increase estrogenic conversion
Both sexes: monitor with labs, not just dose

Geriatric dosing:

Lower starting doses in elderly (5mg for women, 10mg for men)
Titrate slowly based on response
Consider interaction with multiple medications common in older adults
Transdermal route may be preferred for smoother plasma profile

Practical starting recommendation:

Woman over 40 with documented low DHEA-S and specific symptoms: start at 5mg/day oral morning, titrate to 10-15mg based on response and labs at 6-12 weeks
Man over 40 with documented low DHEA-S and specific symptoms: start at 25mg/day oral morning, adjust based on response and labs

Key principle: DHEA should be dosed to restore age-appropriate physiological levels, not supraphysiological elevation. Lower doses that achieve target DHEA-S levels in the upper reference range are clinically equivalent or superior to higher doses, with fewer side effects. Labs confirm appropriate dosing.

Frequently Asked Questions

What is the recommended DHEA dosage?

Dosage for DHEA varies by protocol. Consult a qualified healthcare provider.

How often should I take DHEA?

Administration frequency depends on the specific protocol. Consult current research literature.

Does DHEA need to be cycled?

Cycling requirements depend on the protocol. Follow established research guidelines.

What are DHEA side effects?

Where can I buy DHEA?

Visit our vendor directory to find trusted sources for DHEA.

DHEA Full Profile

Research data, mechanisms, and pricing

Interaction Checker

Check drug & compound interactions

Free 2026 Peptide Cheat Sheet — 50 pages, PDF

Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.

Download Free